{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:38:21Z","timestamp":1786541901300,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Putian City Science and Technology Program Project","award":["2025NJYL009"],"award-info":[{"award-number":["2025NJYL009"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-026-04405-4","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:14:35Z","timestamp":1779318875000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["H3K18 lactylation promotes glycolysis in bladder cancer via inhibiting GNG7 through regulating PI3K-AKT signaling pathway"],"prefix":"10.1186","volume":"24","author":[{"given":"Renfeng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dezhu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weizhen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"4405_CR1","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.euf.2023.05.004","volume":"9","author":"JB Kukreja","year":"2023","unstructured":"Kukreja JB. Non-muscle-invasive Bladder Cancer: Side-by-Side Guideline Comparison. Eur Urol Focus. 2023;9:954\u201356. https:\/\/doi.org\/10.1016\/j.euf.2023.05.004.","journal-title":"Eur Urol Focus"},{"key":"4405_CR2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1590\/S1677-5538.IBJU.2020.99.01","volume":"46","author":"J Hamad","year":"2020","unstructured":"Hamad J, McCloskey H, Milowsky MI, Royce T, Smith A. Bladder preservation in muscle-invasive bladder cancer: a comprehensive review. Int Braz J Urol. 2020;46:169\u201384. https:\/\/doi.org\/10.1590\/S1677-5538.IBJU.2020.99.01.","journal-title":"Int Braz J Urol"},{"key":"4405_CR3","doi-asserted-by":"publisher","unstructured":"Dobruch J, Oszczudlowski M. Bladder Cancer: Current Challenges and Future Directions. Med (Kaunas). 2021;57. https:\/\/doi.org\/10.3390\/medicina57080749.","DOI":"10.3390\/medicina57080749"},{"key":"4405_CR4","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.urolonc.2018.02.017","volume":"36","author":"F Audenet","year":"2018","unstructured":"Audenet F, Attalla K, Sfakianos JP. The evolution of bladder cancer genomics: What have we learned and how can we use it? Urol Oncol. 2018;36:313\u201320. https:\/\/doi.org\/10.1016\/j.urolonc.2018.02.017.","journal-title":"Urol Oncol"},{"key":"4405_CR5","doi-asserted-by":"publisher","first-page":"e76743","DOI":"10.1136\/bmj-2023-076743","volume":"384","author":"A Lopez-Beltran","year":"2024","unstructured":"Lopez-Beltran A, Cookson MS, Guercio BJ, Cheng L. Advances in diagnosis and treatment of bladder cancer. BMJ. 2024;384:e76743. https:\/\/doi.org\/10.1136\/bmj-2023-076743.","journal-title":"BMJ"},{"key":"4405_CR6","doi-asserted-by":"publisher","first-page":"24832","DOI":"10.18632\/oncotarget.8559","volume":"7","author":"J Liu","year":"2016","unstructured":"Liu J, Ji X, Li Z, Yang X, Wang W, Zhang X. G protein gamma subunit 7 induces autophagy and inhibits cell division. Oncotarget. 2016;7:24832\u201347. https:\/\/doi.org\/10.18632\/oncotarget.8559.","journal-title":"Oncotarget"},{"key":"4405_CR7","doi-asserted-by":"publisher","first-page":"20441","DOI":"10.1038\/s41598-021-99544-x","volume":"11","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Yang J, Wang X, Li X. GNG7 and ADCY1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma through bioinformatic-based analyses. Sci Rep. 2021;11:20441. https:\/\/doi.org\/10.1038\/s41598-021-99544-x.","journal-title":"Sci Rep"},{"key":"4405_CR8","doi-asserted-by":"publisher","first-page":"833013","DOI":"10.3389\/fgene.2022.833013","volume":"13","author":"C Fang","year":"2022","unstructured":"Fang C, Zhong R, Qiu C, Zou BB. The Prognostic Value of GNG7 in Colorectal Cancer and Its Relationship With Immune Infiltration. Front Genet. 2022;13:833013. https:\/\/doi.org\/10.3389\/fgene.2022.833013.","journal-title":"Front Genet"},{"key":"4405_CR9","doi-asserted-by":"publisher","first-page":"217156","DOI":"10.1016\/j.canlet.2024.217156","volume":"600","author":"Z Kooshan","year":"2024","unstructured":"Kooshan Z, Cardenas-Piedra L, Clements J, Batra J. Glycolysis, the sweet appetite of the tumor microenvironment. Cancer Lett. 2024;600:217156. https:\/\/doi.org\/10.1016\/j.canlet.2024.217156.","journal-title":"Cancer Lett"},{"key":"4405_CR10","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1080\/15548627.2023.2246356","volume":"19","author":"W Sun","year":"2023","unstructured":"Sun W, Jia M, Feng Y, Cheng X. Lactate is a bridge linking glycolysis and autophagy through lactylation. Autophagy. 2023;19:3240\u201341. https:\/\/doi.org\/10.1080\/15548627.2023.2246356.","journal-title":"Autophagy"},{"key":"4405_CR11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1080\/15548627.2023.2249762","volume":"20","author":"W Li","year":"2024","unstructured":"Li W, Zhou C, Yu L, Hou Z, Liu H, Kong L, et al. Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer. Autophagy. 2024;20:114\u201330. https:\/\/doi.org\/10.1080\/15548627.2023.2249762.","journal-title":"Autophagy"},{"key":"4405_CR12","doi-asserted-by":"publisher","first-page":"103194","DOI":"10.1016\/j.redox.2024.103194","volume":"74","author":"D Wu","year":"2024","unstructured":"Wu D, Spencer CB, Ortoga L, Zhang H, Miao C. Histone lactylation-regulated METTL3 promotes ferroptosis via m6A-modification on ACSL4 in sepsis-associated lung injury. Redox Biol. 2024;74:103194. https:\/\/doi.org\/10.1016\/j.redox.2024.103194.","journal-title":"Redox Biol"},{"key":"4405_CR13","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1039\/c5mb00101c","volume":"11","author":"T Ersahin","year":"2015","unstructured":"Ersahin T, Tuncbag N, Cetin-Atalay R. The PI3K\/AKT\/mTOR interactive pathway. Mol Biosyst. 2015;11:1946\u201354. https:\/\/doi.org\/10.1039\/c5mb00101c.","journal-title":"Mol Biosyst"},{"key":"4405_CR14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo A, Lam HY, Yap K, Jacot W, Jones RH, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22:138. https:\/\/doi.org\/10.1186\/s12943-023-01827-6.","journal-title":"Mol Cancer"},{"key":"4405_CR15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2174\/156800908784293659","volume":"8","author":"A Carnero","year":"2008","unstructured":"Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF. The PTEN\/PI3K\/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets. 2008;8:187\u201398. https:\/\/doi.org\/10.2174\/156800908784293659.","journal-title":"Curr Cancer Drug Targets"},{"key":"4405_CR16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.18632\/oncotarget.240","volume":"2","author":"WH Chappell","year":"2011","unstructured":"Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, et al. Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget. 2011;2:135\u201364. https:\/\/doi.org\/10.18632\/oncotarget.240.","journal-title":"Oncotarget"},{"key":"4405_CR17","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1177\/10600280241241531","volume":"58","author":"AJ Luboff","year":"2024","unstructured":"Luboff AJ, DeRemer DL, Capivasertib. A Novel AKT Inhibitor Approved for Hormone-Receptor-Positive, HER-2-Negative Metastatic Breast Cancer. Ann Pharmacother. 2024;58:1229\u201337. https:\/\/doi.org\/10.1177\/10600280241241531.","journal-title":"Ann Pharmacother"},{"key":"4405_CR18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11306-014-0672-8","volume":"11","author":"QY Lu","year":"2015","unstructured":"Lu QY, Zhang L, Yee JK, Go VW, Lee WN. Metabolic Consequences of LDHA inhibition by Epigallocatechin Gallate and Oxamate in MIA PaCa-2 Pancreatic Cancer Cells. Metabolomics. 2015;11:71\u201380. https:\/\/doi.org\/10.1007\/s11306-014-0672-8.","journal-title":"Metabolomics"},{"key":"4405_CR19","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13059-021-02308-z","volume":"22","author":"J Yu","year":"2021","unstructured":"Yu J, Chai P, Xie M, Ge S, Ruan J, Fan X, et al. Histone lactylation drives oncogenesis by facilitating m(6)A reader protein YTHDF2 expression in ocular melanoma. Genome Biol. 2021;22:85. https:\/\/doi.org\/10.1186\/s13059-021-02308-z.","journal-title":"Genome Biol"},{"key":"4405_CR20","doi-asserted-by":"publisher","unstructured":"Li Y, Huang H, Yu C, Chang Y, Lin S, Wang S, et al. Isoliensinine Induces Ferroptosis in Urothelial Carcinoma Cells via the PI3K\/AKT\/HIF-1alpha Axis: Molecular Evidence from Next-Generation Sequencing. Pharmaceuticals (Basel). 2025;18. https:\/\/doi.org\/10.3390\/ph18071008.","DOI":"10.3390\/ph18071008"},{"key":"4405_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3389\/fphar.2013.00003","volume":"4","author":"RM Bambury","year":"2013","unstructured":"Bambury RM, Rosenberg JE. Advanced Urothelial Carcinoma: Overcoming Treatment Resistance through Novel Treatment Approaches. Front Pharmacol. 2013;4:3. https:\/\/doi.org\/10.3389\/fphar.2013.00003.","journal-title":"Front Pharmacol"},{"key":"4405_CR22","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW, et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct Target Ther. 2021;6:425. https:\/\/doi.org\/10.1038\/s41392-021-00828-5.","journal-title":"Signal Transduct Target Ther"},{"key":"4405_CR23","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/cac2.12158","volume":"41","author":"JZ Wang","year":"2021","unstructured":"Wang JZ, Zhu W, Han J, Yang X, Zhou R, Lu HC, et al. The role of the HIF-1alpha\/ALYREF\/PKM2 axis in glycolysis and tumorigenesis of bladder cancer. Cancer Commun (Lond). 2021;41:560\u201375. https:\/\/doi.org\/10.1002\/cac2.12158.","journal-title":"Cancer Commun (Lond)"},{"key":"4405_CR24","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41419-024-06446-7","volume":"15","author":"M Li","year":"2024","unstructured":"Li M, Yu J, Ju L, Wang Y, Jin W, Zhang R, et al. USP43 stabilizes c-Myc to promote glycolysis and metastasis in bladder cancer. Cell Death Dis. 2024;15:44. https:\/\/doi.org\/10.1038\/s41419-024-06446-7.","journal-title":"Cell Death Dis"},{"key":"4405_CR25","doi-asserted-by":"publisher","first-page":"101140","DOI":"10.1016\/j.jbc.2021.101140","volume":"297","author":"CA Schmidt","year":"2021","unstructured":"Schmidt CA, Fisher-Wellman KH, Neufer PD. From OCR and ECAR to energy: Perspectives on the design and interpretation of bioenergetics studies. J Biol Chem. 2021;297:101140. https:\/\/doi.org\/10.1016\/j.jbc.2021.101140.","journal-title":"J Biol Chem"},{"key":"4405_CR26","doi-asserted-by":"publisher","first-page":"e19635","DOI":"10.1136\/bmjopen-2017-019635","volume":"8","author":"Y He","year":"2018","unstructured":"He Y, Wang N, Zhou X, Wang J, Ding Z, Chen X, et al. Prognostic value of ki67 in BCG-treated non-muscle invasive bladder cancer: a meta-analysis and systematic review. BMJ Open. 2018;8:e19635. https:\/\/doi.org\/10.1136\/bmjopen-2017-019635.","journal-title":"BMJ Open"},{"key":"4405_CR27","doi-asserted-by":"publisher","first-page":"688910","DOI":"10.3389\/fimmu.2021.688910","volume":"12","author":"A Chen","year":"2021","unstructured":"Chen A, Luo Y, Yang Y, Fu J, Geng X, Shi J, et al. Lactylation, a Novel Metabolic Reprogramming Code: Current Status and Prospects. Front Immunol. 2021;12:688910. https:\/\/doi.org\/10.3389\/fimmu.2021.688910.","journal-title":"Front Immunol"},{"key":"4405_CR28","doi-asserted-by":"publisher","unstructured":"Wen ZH, Sung CS, Lin SC, Yao ZK, Lai YC, Liu YW, et al. Intra-Articular Lactate Dehydrogenase A Inhibitor Oxamate Reduces Experimental Osteoarthritis and Nociception in Rats via Possible Alteration of Glycolysis-Related Protein Expression in Cartilage Tissue. Int J Mol Sci. 2023;24. https:\/\/doi.org\/10.3390\/ijms241310770.","DOI":"10.3390\/ijms241310770"},{"key":"4405_CR29","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13046-022-02377-3","volume":"41","author":"M Chi","year":"2022","unstructured":"Chi M, Liu J, Mei C, Shi Y, Liu N, Jiang X, et al. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K\/AKT pathway in bladder cancer. J Exp Clin Cancer Res. 2022;41:175. https:\/\/doi.org\/10.1186\/s13046-022-02377-3.","journal-title":"J Exp Clin Cancer Res"},{"key":"4405_CR30","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.7150\/ijbs.89942","volume":"20","author":"F Fontana","year":"2024","unstructured":"Fontana F, Giannitti G, Marchesi S, Limonta P. The PI3K\/Akt Pathway and Glucose Metabolism: A Dangerous Liaison in Cancer. Int J Biol Sci. 2024;20:3113\u201325. https:\/\/doi.org\/10.7150\/ijbs.89942.","journal-title":"Int J Biol Sci"},{"key":"4405_CR31","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1016\/j.jmb.2016.08.002","volume":"428","author":"V Syrovatkina","year":"2016","unstructured":"Syrovatkina V, Alegre KO, Dey R, Huang XY. Regulation, Signaling, and Physiological Functions of G-Proteins. J Mol Biol. 2016;428:3850\u201368. https:\/\/doi.org\/10.1016\/j.jmb.2016.08.002.","journal-title":"J Mol Biol"},{"key":"4405_CR32","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1186\/s12885-023-11265-8","volume":"23","author":"J Zheng","year":"2023","unstructured":"Zheng J, Zhang W, Zhang J. Establishment of a new prognostic risk model of GNG7 pathway-related molecules in clear cell renal cell carcinoma based on immunomodulators. BMC Cancer. 2023;23:864. https:\/\/doi.org\/10.1186\/s12885-023-11265-8.","journal-title":"BMC Cancer"},{"key":"4405_CR33","doi-asserted-by":"publisher","first-page":"20002","DOI":"10.1002\/jcp.28597","volume":"234","author":"S Xu","year":"2019","unstructured":"Xu S, Zhang H, Liu T, Chen Y, He D, Li L. G Protein gamma subunit 7 loss contributes to progression of clear cell renal cell carcinoma. J Cell Physiol. 2019;234:20002\u201312. https:\/\/doi.org\/10.1002\/jcp.28597.","journal-title":"J Cell Physiol"},{"key":"4405_CR34","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/1476-4598-12-152","volume":"12","author":"S Ganapathy-Kanniappan","year":"2013","unstructured":"Ganapathy-Kanniappan S, Geschwind JF. Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer. 2013;12:152. https:\/\/doi.org\/10.1186\/1476-4598-12-152.","journal-title":"Mol Cancer"},{"key":"4405_CR35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13046-023-02614-3","volume":"42","author":"J Lv","year":"2023","unstructured":"Lv J, Li K, Yu H, Han J, Zhuang J, Yu R, et al. HNRNPL induced circFAM13B increased bladder cancer immunotherapy sensitivity via inhibiting glycolysis through IGF2BP1\/PKM2 pathway. J Exp Clin Cancer Res. 2023;42:41. https:\/\/doi.org\/10.1186\/s13046-023-02614-3.","journal-title":"J Exp Clin Cancer Res"},{"key":"4405_CR36","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1097\/CAD.0000000000001394","volume":"33","author":"Z Yuan","year":"2022","unstructured":"Yuan Z, Ren R, Xu Z. G protein subunit gamma 5 promotes the proliferation, metastasis and glycolysis of breast cancer cells through the Wnt\/beta-catenin pathway. Anticancer Drugs. 2022;33:1004\u201311. https:\/\/doi.org\/10.1097\/CAD.0000000000001394.","journal-title":"Anticancer Drugs"},{"key":"4405_CR37","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.freeradbiomed.2024.06.021","volume":"222","author":"Y Si","year":"2024","unstructured":"Si Y, Ou H, Jin X, Gu M, Sheng S, Peng W, et al. G protein pathway suppressor 2 suppresses aerobic glycolysis through RACK1-mediated HIF-1alpha degradation in breast cancer. Free Radic Biol Med. 2024;222:478\u201392. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2024.06.021.","journal-title":"Free Radic Biol Med"},{"key":"4405_CR38","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.ijbiomac.2021.04.082","volume":"182","author":"H Zheng","year":"2021","unstructured":"Zheng H, Tian H, Yu X, Ren P, Yang Q. G protein gamma 7 suppresses progression of lung adenocarcinoma by inhibiting E2F transcription factor 1. Int J Biol Macromol. 2021;182:858\u201365. https:\/\/doi.org\/10.1016\/j.ijbiomac.2021.04.082.","journal-title":"Int J Biol Macromol"},{"key":"4405_CR39","doi-asserted-by":"publisher","first-page":"7849","DOI":"10.1080\/21655979.2021.1976896","volume":"12","author":"X Zhao","year":"2021","unstructured":"Zhao X, Zhang XC, Zang K, Yu ZH. MicroRNA miR-19b-3p mediated G protein gamma subunit 7 (GNG7) loss contributes lung adenocarcinoma progression through activating Hedgehog signaling. Bioengineered. 2021;12:7849\u201358. https:\/\/doi.org\/10.1080\/21655979.2021.1976896.","journal-title":"Bioengineered"},{"key":"4405_CR40","doi-asserted-by":"publisher","first-page":"1211221","DOI":"10.3389\/fimmu.2023.1211221","volume":"14","author":"H Wu","year":"2023","unstructured":"Wu H, Huang H, Zhao Y. Interplay between metabolic reprogramming and post-translational modifications: from glycolysis to lactylation. Front Immunol. 2023;14:1211221. https:\/\/doi.org\/10.3389\/fimmu.2023.1211221.","journal-title":"Front Immunol"},{"key":"4405_CR41","doi-asserted-by":"publisher","first-page":"12866","DOI":"10.3390\/cimb46110766","volume":"46","author":"Y He","year":"2024","unstructured":"He Y, Xiang L, Yuan J, Yan H. Lactylation Modification as a Promoter of Bladder Cancer: Insights from Multi-Omics Analysis. Curr Issues Mol Biol. 2024;46:12866\u201385. https:\/\/doi.org\/10.3390\/cimb46110766.","journal-title":"Curr Issues Mol Biol"},{"key":"4405_CR42","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12943-023-01856-1","volume":"22","author":"B Xie","year":"2023","unstructured":"Xie B, Lin J, Chen X, Zhou X, Zhang Y, Fan M, et al. CircXRN2 suppresses tumor progression driven by histone lactylation through activating the Hippo pathway in human bladder cancer. Mol Cancer. 2023;22:151. https:\/\/doi.org\/10.1186\/s12943-023-01856-1.","journal-title":"Mol Cancer"},{"key":"4405_CR43","doi-asserted-by":"publisher","first-page":"101059","DOI":"10.1016\/j.drup.2024.101059","volume":"73","author":"F Li","year":"2024","unstructured":"Li F, Zhang H, Huang Y, Li D, Zheng Z, Xie K, et al. Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer. Drug Resist Updat. 2024;73:101059. https:\/\/doi.org\/10.1016\/j.drup.2024.101059.","journal-title":"Drug Resist Updat"},{"key":"4405_CR44","doi-asserted-by":"publisher","first-page":"819128","DOI":"10.3389\/fonc.2022.819128","volume":"12","author":"Y Peng","year":"2022","unstructured":"Peng Y, Wang Y, Zhou C, Mei W, Zeng C. PI3K\/Akt\/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway? Front Oncol. 2022;12:819128. https:\/\/doi.org\/10.3389\/fonc.2022.819128.","journal-title":"Front Oncol"},{"key":"4405_CR45","doi-asserted-by":"publisher","first-page":"110553","DOI":"10.1016\/j.cellsig.2022.110553","volume":"102","author":"Y Li","year":"2023","unstructured":"Li Y, Zhou Y, Huang M, Wang Z, Liu D, Liu J, et al. DHCR7 promotes tumorigenesis via activating PI3K\/AKT\/mTOR signalling pathway in bladder cancer. Cell Signal. 2023;102:110553. https:\/\/doi.org\/10.1016\/j.cellsig.2022.110553.","journal-title":"Cell Signal"},{"key":"4405_CR46","doi-asserted-by":"publisher","first-page":"e2305922","DOI":"10.1002\/advs.202305922","volume":"11","author":"X Zheng","year":"2024","unstructured":"Zheng X, Chen J, Deng M, Ning K, Peng Y, Liu Z, et al. G3BP1 and SLU7 Jointly Promote Immune Evasion by Downregulating MHC-I via PI3K\/Akt Activation in Bladder Cancer. Adv Sci (Weinh). 2024;11:e2305922. https:\/\/doi.org\/10.1002\/advs.202305922.","journal-title":"Adv Sci (Weinh)"},{"key":"4405_CR47","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/978-1-4939-7234-0_23","volume":"1655","author":"A Sathe","year":"2018","unstructured":"Sathe A, Nawroth R. Targeting the PI3K\/AKT\/mTOR Pathway in Bladder Cancer. Methods Mol Biol. 2018;1655:335\u201350. https:\/\/doi.org\/10.1007\/978-1-4939-7234-0_23.","journal-title":"Methods Mol Biol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04405-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04405-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04405-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:07:01Z","timestamp":1786540021000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04405-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4405"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04405-4","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of The 95th Hospital of Putian. All animal experiments complied with the ARRIVE guidelines. All methods were carried out in accordance with relevant guidelines and regulations.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"330"}}